Resultados de búsqueda - Linda Wernevik

A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II por Jane Knöchel, Catarina Nilsson, Björn Carlsson, Linda Wernevik, Alexis Hofherr, Peter Gennemark, Rasmus Jansson‐Löfmark, Rikard Isaksson, Tina Rydén‐Bergsten, Bengt Hamrén, Dinko Rekić

Connect to this object online.

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial por Iain B. Squire, Anders Gabrielsen, Peter J. Greasley, Linda Wernevik, Judith Hartleib‐Geschwindner, Julie Holden, Susanne Johansson, Anna Rudvik, José Sánchez, Krister Bamberg, Johanna Melin, Andrew Whittaker

Connect to this object online.

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study por Andrew Whittaker, Åsa M. Kragh, Judith Hartleib‐Geschwindner, Muna Albayaty, Anna Backlund, Peter J. Greasley, Maria Heijer, Magnus Kjaer, Pablo Forte, Robert Unwin, Linda Wernevik, Hans Ericsson

Connect to this object online.